Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: biotechnology

Baltimore-based Cerecor obtains depression drug rights

Cerecor Inc., of Baltimore, a biopharmaceutical company focused on developing and commercializing prescription drugs involving the human nervous system, said it has acquired from Merck & Co. the exclusive, worldwide rights to a drug called MK-0657, which it said has the potential to treat depression. Merck originally developed MK-0657 for treatment of Parkinson’s disease.

Read More »

FDA OKs Neuralstem’s ALS clinical trial

Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, said it received approval from the Food and Drug Administration to begin a Phase II trial using spinal cord-derived human neural stem cells to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

Read More »

PharmAthene nerve agent blocker tested

PharmAthene Inc., of Annapolis, a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the company's recombinant butyrylcholinesterase (rBChE) bioscavenger.

Read More »

Northwest Bio’s loss doubles in a year

Northwest Biotherapeutics Inc., of Bethesda, a development-stage biotechnology company focused on developing therapies to improve the body’s immune response to cancer, reported a net loss of $67.3 million, or 5.72 per share, in the 12 months ended Dec. 31, 2012, compared to a loss of $32.8 million, or $5.58 per share, for the same period in 2011.

Read More »

Neuralstem obtains debt financing

Neuralstem Inc., of Rockville, which is developing products to treat central nervous system disorders with patented stem cell technology, said it secured $8 million in debt financing with Hercules Technology Growth Capital to fund its capital budget through late 2014.

Read More »